Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Upregulated lung cancer 10 (URLC10)
- Target
- URLC10
- Molecular classification
- Cancer/testis antigen, Other
01
Overview
Upregulated lung cancer 10 (URLC10) is a cancer/testis antigen that is highly expressed in various malignancies, particularly non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and pancreatic cancer, while remaining virtually absent in normal adult tissues except for the testis (PubMed: 15343322). It plays a significant role in promoting cell proliferation and survival, and its knockdown has been shown to inhibit the growth of cancer cells (PubMed: 15343322). Due to its restricted expression pattern and essential role in tumor cell viability, URLC10 is considered an ideal target for cancer immunotherapy, specifically for the development of peptide-based vaccines (PubMed: 21858018). Therapeutic strategies currently focus on using URLC10-derived peptides to elicit a specific cytotoxic T-lymphocyte (CTL) response to eliminate tumor cells expressing the antigen (PubMed: 21858018). Clinical trials have explored its use in combination with other cancer/testis antigens to treat advanced cancers, demonstrating its potential as a viable therapeutic target (PubMed: 24633677).
- Other names
- LY6K-AS1C10orf116Cancer/testis antigen 146CT146
02
Mechanism of action
Induction of cytotoxic T-lymphocyte (CTL) response against URLC10-expressing tumor cells
03
Biological functions
Cell proliferationCell cycle regulationSignal transduction
04
Disease associations
CancerNon-small cell lung cancerSmall cell lung cancerPancreatic cancer
05
Safety considerations
Injection site reactionsPotential for autoimmune response (though limited by restricted normal tissue expression)
06
Interacting drugs
URLC10-177 peptide vaccine
07
Biomarkers
URLC10 expression levelsURLC10-specific cytotoxic T-lymphocyte (CTL) activity
Beyond the preview
Go deeper on Upregulated lung cancer 10 (URLC10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Upregulated lung cancer 10 (URLC10).